A CATT negative result after treatment for human african trypanosomiasis is no indication for cure

PLoS Neglected Tropical Diseases

Volumn 4, Issue 1, 2010, Pages

  Lejon, Veerle ^a   Ngoyi, Dieudonné Mumba ^b   Boelaert, Marleen ^a   Büscher, Philippe ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Institut National de Recherche Biomedicale   (Congo)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; ANTITRYPANOSOMAL AGENT; PROTOZOON ANTIBODY;

AFRICAN TRYPANOSOMIASIS; AGGLUTINATION TEST; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CARD AGGLUTINATION TEST FOR TRYPANOSOMIASIS; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; RELAPSE; SENSITIVITY ANALYSIS; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TRYPANOSOMA; BLOOD; IMMUNOLOGY; METHODOLOGY; PARASITOLOGY;

AGGLUTINATION TESTS; ANTIBODIES, PROTOZOAN; EFLORNITHINE; HUMANS; MELARSOPROL; PENTAMIDINE; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 76249116389     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000590     Document Type: Article

References (12)

1. WHO (1998) Control and surveillance of African trypanosomiasis. WHO Technical Report Series 881: 1-113.
2. Ngampo S (1992) Suivi post-thérapeutique des malades trypanosomés à T.b. gambiense. Problèmes et perspectives [dissertation]. Instituut voor Tropische Geneeskunde, Antwerpen. 45 p.
3. Miézan TW, Djé NN, Doua F, Boa F (2002) Trypanosomose humaine africaine en Côte d'Ivoire: caractéristiques biologiques après traitement. A propos de 812 cas traités dans le foyer de Daloa (Côte d'Ivoire). Bull Soc Pathol Exot Fil 95: 362-365.
4. Robays J, Lefevre P, Lutumba P, Lubanza S, Kande Betu-Ku-Mesu V, et al. (2007) Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Trop Med Int Health 12: 290-298.
5. World Health Organization (2007) Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis. Geneva: WHO/CDS/NTD/IDM/2007.1. 73 p.
6. Magnus E, Vervoort T, Van Meirvenne N (1978) A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T.b. gambiense trypanosomiasis. Ann Soc Belg Méd Trop 58: 169-176.
7. Chappuis F, Loutan L, Simarro P, Lejon V, Büscher P (2005) Options for the field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 18: 133-146.
8. Simarro PP, Jannin J, Cattand P (2008) Eliminating human African trypanosomiasis: Where do we stand and what comes next? PLoS Medicine 5: 174-180.
9. Paquet C, Ancelle T, Gastellu-Etchegorry M, Castilla J, Harndt I (1992) Persistence of antibodies to Trypanosoma brucei gambiense after treatment of human trypanosomiasis in Uganda. Lancet 340: 250.
10. Pépin J, Guern C, Mercier D, Moore P (1986) Utilisation du Testryp CATT pour le depistage de la trypanosomiase a Nioki, Zaïre. Ann Soc Belg Méd Trop 66: 213-224.
11. Mumba Ngoyi D, Lejon V, Pyana P, Boelaert M, Ilunga M, et al. (2009) How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness? J Infect Dis. In press.
12. Frézil J-L, Coulm J, Alary J-C (1978) L'immunofluorescence indirecte dans la surveillance thérapeutique des trypanosomoses (note préliminaire). Bull Soc Pathol Exot 71: 440-445.